100s of titles, one news app for just $10 a month.
Dive Deeper:
Esperion Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Esperion Therapeutics (NASDAQ:ESPR) posted sales of $18.84 million. Earnings were up 12.88%, but…
PTC Therapeutics's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, PTC Therapeutics's (NASDAQ:PTCT) reported sales totaled $148.74 million. Despite a 11.54% increase…
Sage Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Sage Therapeutics's (NASDAQ:SAGE) reported sales totaled $1.58 million. Despite a 2.13% increase…
CytoSorbents's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, CytoSorbents's (NASDAQ:CTSO) reported sales totaled $8.69 million. Despite a 3.66% increase in…
One subscription that gives you access to news from hundreds of sites
Workiva's Return On Capital Employed Insights
Benzinga Pro data, Workiva (NYSE:WK) reported Q1 sales of $129.67 million. Earnings fell to a loss of $18.49 million, resulting…
Triton International's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Triton International (NYSE:TRTN) posted Q1 earnings of $194.26 million, an increase from Q4 of 2.0%.…
Get all your news in one place
Latest Business news:
Travel patterns have changed for good. Transport systems should, too
Enough with all the radii
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
The cryptocurrency sell-off has exposed those swimming naked
And investors are beginning to discriminate
No slump for pump and dump cryptocurrency gangs
Paris (AFP) - In a sleepy corner of the crypto-economy, the value of an obscure coin called Enzyme was tumbling…
ASX slip after rising on tech, US stocks rally on rate rise outlook
Australian shares fall after a positive start on Thursday, following a strong session on Wall Street as investors cling onto…
Apple will finally make deleting your app accounts less of a nightmare
For apps that offer account creation, a new account deletion policy goes into effect at the end of June.
From analysis to good news, read the world’s best news in one place
Pay ‘with a smile or a wave’: Mastercard face recognition system
Mastercard’s “smile to pay” system, announced last week, is supposed to save time for customers at checkouts. It is being…
Power prices to surge up to 18.3 per cent as energy market turmoil flows through to households
Benchmark power prices will rise by up to 18.3 per cent as the energy industry watchdog seeks to pass on…

Kymera Therapeutics's Return On Capital Employed Insights

By Benzinga Insights

Benzinga Pro data, Kymera Therapeutics (NASDAQ:KYMR) reported Q1 sales of $9.62 million. Earnings fell to a loss of $36.68 million, resulting in a 8.21% decrease from last quarter. In Q4, Kymera Therapeutics brought in $15.28 million in sales but lost $33.90 million in earnings.

What Is ROCE?

Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q1, Kymera Therapeutics posted an ROCE of -0.09%.

It is important to keep in mind that ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but does not account for factors that could affect earnings and sales in the near future.

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Kymera Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For Kymera Therapeutics, a negative ROCE ratio of -0.09% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Analyst Predictions

Kymera Therapeutics reported Q1 earnings per share at $-0.71/share, which did not meet analyst predictions of $-0.66/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
Esperion Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Esperion Therapeutics (NASDAQ:ESPR) posted sales of $18.84 million. Earnings were up 12.88%, but…
PTC Therapeutics's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, PTC Therapeutics's (NASDAQ:PTCT) reported sales totaled $148.74 million. Despite a 11.54% increase…
Sage Therapeutics Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Sage Therapeutics's (NASDAQ:SAGE) reported sales totaled $1.58 million. Despite a 2.13% increase…
CytoSorbents's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q1, CytoSorbents's (NASDAQ:CTSO) reported sales totaled $8.69 million. Despite a 3.66% increase in…
One subscription that gives you access to news from hundreds of sites
Workiva's Return On Capital Employed Insights
Benzinga Pro data, Workiva (NYSE:WK) reported Q1 sales of $129.67 million. Earnings fell to a loss of $18.49 million, resulting…
Triton International's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Triton International (NYSE:TRTN) posted Q1 earnings of $194.26 million, an increase from Q4 of 2.0%.…
Get all your news in one place